Janzic U - Search Results

1

Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study).

Janzic U, Maimon Rabinovich N, Shalata W, Kian W, Szymczak K, Dziadziuszko R, Jakopovic M, Mountzios G, Pluzanski A, Araujo A, Charpidou A, Daher S, Agbarya A. Janzic U, et al. Curr Oncol. 2024 Jul 30;31(8):4369-4381. doi: 10.3390/curroncol31080326. Curr Oncol. 2024. PMID: 39195309 Free PMC article.

2

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.

Illini O, Saalfeld FC, Christopoulos P, Duruisseaux M, Vikström A, Peled N, Demedts I, Dudnik E, Eisert A, Hashemi SMS, Janzic U, Kian W, Mohorcic K, Mohammed S, Silvoniemi M, Rothschild SI, Schulz C, Wesseler C, Addeo A, Armster K, Itchins M, Ivanović M, Kauffmann-Guerrero D, Koivunen J, Kuon J, Pavlakis N, Piet B, Sebastian M, Velthaus-Rusik JL, Wannesson L, Wiesweg M, Wurm R, Albers-Leischner C, Aust DE, Janning M, Fabikan H, Herold S, Klimova A, Loges S, Sharapova Y, Schütz M, Weinlinger C, Valipour A, Overbeck TR, Griesinger F, Jakopovic M, Hochmair MJ, Wermke M. Illini O, et al. Among authors: janzic u. Int J Mol Sci. 2024 Apr 3;25(7):3992. doi: 10.3390/ijms25073992. Int J Mol Sci. 2024. PMID: 38612799 Free PMC article.

3

Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes.

Janzic U, Janzic A, Agbarya A, Bidovec-Stojkovic U, Mohorcic K, Caks M, Korosec P, Rijavec M, Skof E. Janzic U, et al. Biomedicines. 2024 Feb 27;12(3):535. doi: 10.3390/biomedicines12030535. Biomedicines. 2024. PMID: 38540148 Free PMC article.

4

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments.

Agbarya A, Sarel I, Ziv-Baran T, Schwartz O, Shechtman Y, Kozlener E, Khoury R, Sheikh-Ahmad M, Saiegh L, Swaid F, Ahmad AA, Janzic U, Brenner R. Agbarya A, et al. Among authors: janzic u. Diseases. 2023 Sep 26;11(4):128. doi: 10.3390/diseases11040128. Diseases. 2023. PMID: 37873772 Free PMC article.

5

Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.

Ljubicic L, Janzic U, Unk M, Terglav AS, Mohorcic K, Seiwerth F, Bitar L, Badovinac S, Plestina S, Korsic M, Kukulj S, Samarzija M, Jakopovic M. Ljubicic L, et al. Among authors: janzic u. Radiol Oncol. 2023 Sep 4;57(3):397-404. doi: 10.2478/raon-2023-0040. eCollection 2023 Sep 1. Radiol Oncol. 2023. PMID: 37665737 Free PMC article.

6

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.

Janzic U, Shalata W, Szymczak K, Dziadziuszko R, Jakopovic M, Mountzios G, Płużański A, Araujo A, Charpidou A, Agbarya A. Janzic U, et al. Int J Mol Sci. 2023 Aug 16;24(16):12840. doi: 10.3390/ijms241612840. Int J Mol Sci. 2023. PMID: 37629023 Free PMC article.

7

A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers.

Janzic U, Bidovec-Stojkovic U, Korosec P, Mohorcic K, Mrak L, Caks M, Ravnik M, Skof E, Rijavec M. Janzic U, et al. Vaccines (Basel). 2023 May 23;11(6):1017. doi: 10.3390/vaccines11061017. Vaccines (Basel). 2023. PMID: 37376406 Free PMC article.

8

Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).

Janžič U, Turnšek N, Dediu M, Donev IS, Lupu R, Teodorescu G, Ciuleanu TE, Pluzanski A. Janžič U, et al. Curr Oncol. 2022 Aug 17;29(8):5833-5845. doi: 10.3390/curroncol29080460. Curr Oncol. 2022. PMID: 36005198 Free PMC article.

9

Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.

Turnsek N, Devjak R, Edelbaher N, Osrajnik I, Unk M, Vidovic D, Jeric T, Janzic U. Turnsek N, et al. Among authors: janzic u. Radiol Oncol. 2022 Aug 14;56(3):371-379. doi: 10.2478/raon-2022-0025. Radiol Oncol. 2022. PMID: 35853681 Free PMC article.

10

Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination.

Janzic U, Bidovec-Stojkovic U, Mohorcic K, Mrak L, Dovnik NF, Ivanovic M, Ravnik M, Caks M, Skof E, Debeljak J, Korosec P, Rijavec M. Janzic U, et al. Future Oncol. 2022 Jul;18(23):2537-2550. doi: 10.2217/fon-2022-0148. Epub 2022 Jun 9. Future Oncol. 2022. PMID: 35678621 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters